Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial data for antibody-drug conjugates (ADCs); sequence optimization, combinatorial therapy utilization, and identification of when and in which patients to use ADCs; and anticipation, recognition, and management of treatment-related adverse events (TRAEs) in patients with metastatic urothelial cancer (mUC). Join our expert faculty for this 60-minute activity designed to help clinicians stay abreast of emerging trial data and evolving treatment guidelines, as well as effectively manage agent-specific AEs, to optimize care for their patients with mUC.

Learn more: https://www.ceconcepts.com/activity/tailoring-patient-care-using-novel-agents-in-metastatic-urothelial-carcinoma-strategies-for-the-interprofessional-team/